Actively Recruiting

Age: 18Years +
All Genders
ID07264426

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

Led by argenx · Updated on 2026-04-23

200

Participants Needed

23

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying the real-world effectiveness of efgartigimod in treating adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The study aims to understand how patients respond to the treatment over time, describe their treatment experiences, and assess their use of healthcare services. This observational study follows participants for up to two years after they begin efgartigimod treatment. Participants will receive efgartigimod according to the approved treatment guidelines in their country, with treatment decisions made by their doctors as part of usual care. Since this is a noninterventional study, no specific treatments are assigned by the researchers; instead, the study observes how patients use efgartigimod in routine practice. Throughout the study, participants will be monitored for changes in their disability and quality of life using measures like the adjusted inflammatory neuropathy cause and treatment (aINCAT) score, I-RODS, grip strength, and EQ-5D values. These assessments will occur over a period of up to two years and three months, helping researchers understand the impact of efgartigimod on patients living with CIDP.

CONDITIONS

Brief Title

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged 60 years or older at the time of informed consent
  • Diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
  • Planned to receive efgartigimod treatment within the approved CIDP treatment label in the participant's country
  • Efgartigimod treatment-nafve at the time of screening
Not Eligible

You will not qualify if you...

  • Polyradiculoneuropathy caused by other conditions
  • Currently participating in any interventional clinical study or planning to participate before starting efgartigimod

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to 2 years and 3 months

Participants who undergo routine efgartigimod treatment for CIDP are observed over time.

Regular visits according to country-specific treatment guidelines

Trial Site Locations

Total: 23 locations

1

PPD Virtual

Wilmington, North Carolina, United States, 28401

Actively Recruiting

2

Jüdisches Krankenhaus Berlin

Berlin, Germany, 13347

Actively Recruiting

3

Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH

Bochum, Germany, 44789

Actively Recruiting

4

UK-RUB - Katholisches Klinikum Bochum - St. Josef Hospital

Bochum, Germany, 44791

Actively Recruiting

5

Universitätsklinikum Köln

Cologne, Germany, 50937

Actively Recruiting

6

Universitätsklinikum Düsseldorf

Düsseldorf, Germany, 40225

Actively Recruiting

7

Universitätsklinikum Frankfurt

Frankfurt, Germany, 60590

Actively Recruiting

8

UKGM - Universitätsklinikum Gießen und Marburg GmbH

Giessen, Germany, 35392

Actively Recruiting

9

Universitätsmedizin Göttingen

Göttingen, Germany, 37075

Actively Recruiting

10

Universitätsklinikum Hamburg Eppendorf

Hamburg, Germany, 20251

Actively Recruiting

11

Neurologie Neuer Wall - Dr.Bredow & Partner

Hamburg, Germany, 20354

Actively Recruiting

12

Medizinische Hochschule Hannover

Hanover, Germany, 30625

Actively Recruiting

13

Universitatsklinikum des Saarlandes

Homburg, Germany, 66424

Actively Recruiting

14

Universitätsklinikum Magdeburg A.ö.R.

Magdeburg, Germany, 39120

Actively Recruiting

15

Universitätsklinikum Mannheim

Mannheim, Germany, 68167

Actively Recruiting

16

Universitätsklinikum Gießen und Marburg GmbH - Standort Marburg

Marburg, Germany, 35043

Actively Recruiting

17

Mühlenkreiskliniken - Johannes Wesling Klinikum Minden

Minden, Germany, 32429

Actively Recruiting

18

Friedrich-Baur-Institute München

München, Germany, 80336

Actively Recruiting

19

Alexianer St. Josef Potsdam GmbH

Potsdam, Germany, 14471

Actively Recruiting

20

Immanuel Klinik Rüdersdorf

Rüdersdorf, Germany, 15562

Actively Recruiting

21

Diakonie-Klinikum Schwäbisch Hall gGmbH

Schwäbisch Hall, Germany, 74523

Actively Recruiting

22

Universitätsklinikum Tübingen

Tübingen, Germany, 72076

Actively Recruiting

23

Universitätsklinikum Ulm

Ulm, Germany, 89081

Actively Recruiting

Loading map...

Research Team

S

Sabine Coppieters, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Ev...

Chronic Inflammatory Demyelinating Polyneuropathy

Actively Recruiting

73 locations

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled St...

Chronic Inflammatory Demyelinating Polyneuropathy

Actively Recruiting

56 locations

Study to Evaluate Pharmacokinetics and Safety of XEMBIFY Ver...

CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)

Actively Recruiting

5 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here